DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Bibliographic Details
Main Authors: Zhu, Jian, Wang, Yuyan, Duan, Jianchun, Bai, Hua, Wang, Zhijie, Wei, Lai, Zhao, Jun, Zhuo, Minglei, Wang, Shuhang, Yang, Lu, An, Tongtong, Wu, Meina, Wang, Jie
Format: Online
Language:English
Published: BioMed Central 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524045/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524045/

Similar Items